Genentech, a unit of Roche Holding AG (RHHBY) Friday said the U.S. Food and Drug Administration or FDA has approved its Vabysmo prefilled syringe (PFS) to treat age-related macular degeneration (AMD) diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
Vabysmo PFS, which delivers the same medicine as the currently available Vabysmo vials, will be available in the coming months, the company said in a statement.
Vabysmo is currently approved in more than 95 countries for wet AMD and DME, and in several countries, including the U.S. and Japan, for RVO.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.